Shares of pharmaceutical company Zosano Pharma ($ZSAN) were trading higher this morning. Reason is the announcement of a feasibility study agreement with Mitsubishi Tanabe Pharma Corporation ($MTZPY), a Japanese pharmaceutical company that develops innovative therapies and produces medicines for heart failure, hypertension, autoimmune diseases, stomach and kidney diseases. Zosano has recently been in the news for the development of a microneedle transdermal patch system that allows it to deliver the formulations of existing drugs through the skin for the treatment of a variety of indications. Zosano is also the developer of the clinical asset Qtrypta (also known as M207), a proprietary formulation of zolmitriptan that uses a self-adhesive dermally applied Microarray technology. Simply said, it’s an acute treatment for patients with migraine. It’s currently under review by the FDA and expected to be approved around 2021.
Evaluating the feasibility of a pharmaceutical agent
Zosano is excited about the new partnership as it enables the company to combine its patented microneedle transdermal drug delivery platform with the drug development candidate of Mitsubishi Tanabe Pharma Corp. The goal is to be able to make a difference with the platform by sharing each other’s knowledge and expertise. This must be able to meet the demand for certain medical needs. Thanks to the agreement, Zosano will start evaluating the feasibility of a pharmaceutical agent that Mitsubishi Tanabe Pharma Corp. has developed for administration to humans with the microneedle transdermal patch system. The research and development activities defined will include the vitro and vivo phases. Mitsubishi Tanabe Pharma Corp. will have the option to negotiate an exclusive license for the relevant Zosano technologies. This will be clarified as soon as the results of the research are known.
At this time, the companies do not intend to disclose the financial terms and identity of the Mitsubishi Tanabe molecule and development program.
This is Mitsubishi Tanabe Pharma Corp.
The company has been active in the pharmaceutical sector since 2007. The business philosophy is “contributing to the healthier lives of people around the world through the creation of pharmaceuticals.” With the aging population and declining birth rates, the company believes that international pressure for more cost-effective medicines has increased significantly. Advances in science have enabled therapeutic agents to treat diseases that were recently untreatable.
There’s also a downside to this progress, as technology and research costs have risen in recent years. Mitsubishi Tanabe Pharma Corp. wants to realize more pharmaceutical activities in which to search for new medication without the costs being insurmountable. This challenge requires a lot of innovation and expertise. The company therefore seeks partnerships with both academic and business partners. Thanks to Zosano Pharma this has now led to the feasibility study agreement of the microneedle transdermal patch system.
Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.